The great explorer of the truth, the master-builder of human happiness no one rejects dislikes avoids pleasure itself because it is pleasure but because know who do not those how to pursue pleasures rationally encounter consequences that are extremely painful desires to obtain.
Read MoreNorth American Animal Model Market revenue to hit $18.1 Bn by 2027
Published Date: 2021-06-14
Request a sample
North American Animal Model Market size is poised to surpass USD 18.1 billion by 2027, according to a latest forecast report by Graphical Research.
Utilization of CRISPR as a powerful tool in the field of biomedical research across North American regional will stimulate the market growth. The rise of CRISPR/Cas9 technology has enabled the generation of any animal model and has revolutionized the generation of transgenic animals. These factors are potentially augmenting the adoption, demand and production of animal models. As per a recently published article, the prevalence of progeria disease in North America led to the adoption of CRISPR technology by the scientists to obtain the treatment for the disease. Moreover, genome-modified pigs have also been engineered using CRISPR technique. Currently, CRISPR genome editing is under evaluation for therapeutic applications such as tissue regeneration, gene therapy, obesity and metabolism, and HIV and viral disease. The CRISPR/Cas9 system has potential to target the mammalian genome. This system enables the creation of specialized mutations in relatively shorter time along with the capability to develop homozygous mutant. It enables the researchers to generate animal models that facilitate specific genome targeting. Thus, the emergence of CRISPR has augmented the demand for animal models across the region.
Based on animal type, the market is segmented as mice, rats, fish, birds, cattle, pigs, amphibians, guinea pigs, dogs, cats, rabbits, monkeys, sheep, hamsters and others. Rats segment held substantial share in 2020 and was valued at more than 854 million. The majority market share is owing to their growing demand for research such as diabetes research and immunology research. A wide variety of genetically modified rat models can be generated and are considered ideal for conduction of experiments. The animal is regarded as an optimal model for cardiovascular disease studies, especially for stroke and hypertension. The physiology of rat is easier to assess and corresponding to human conditions in several aspects. Use of rats as disease models in breast cancer studies are considered superior to mouse owing to their better hormone response with histopathology and premalignant stages resembling closely to human diseases. Also in diabetes studies, rat model represents human behavior. Furthermore, the demand for rat models is huge as they have advanced cognitive ability and capability of learning different tasks that aid in cognitive research.
Based on technology, the market is segmented as CRISPR, microinjection, embryonic stem cell injection, nuclear transfer and other. Microinjection segment is anticipated to expand at a CAGR of 8.2% from 2021 to 2027. Transgenic organisms can be generated through microinjection technique by injecting genetic material into the nucleus of a fertilized oocyte. Additionally, microinjection technique is widely adopted owing to its ability to downregulate the gene expression in animal models. Microinjection technique is preferred choice in low quality cells and increases the embryo survival chances. Furthermore, microinjection technique is host-range independent and is preferably utilized to study the gene expression using mouse animal models.
Browse detailed statistical insights from the report, “North America Animal Model Market Forecast 2027 By Technology (CRISPR, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer), By Animal Type (Mice, Rats, Fish, Birds, Cattles, Pigs, Amphibians, Guinea Pigs, Dogs, Cats, Rabbits, Monkeys, Sheep, Hamsters), By Application (Research & Development {Infectious Disease, Immunological Diseases, Cancer, Cardiovascular Diseases, Diabetes, Genetic Diseases, Neurological Diseases, Obesity, NAFLD/NASH, Renal Disease, Diabetic Eye Disease, Fibrosis, Microbiome}, Production and Quality Control, Academics, Preclinical Applications {Infectious Disease, Immunological Diseases, Cancer, Cardiovascular Diseases, Diabetes, Genetic Diseases, Neurological Diseases, Obesity, NAFLD/NASH, Renal Disease, Diabetic Eye Disease, Fibrosis, Microbiome}), By Use (Human, Veterinary), By End-use (Companies {Pharmaceutical, Biotechnology, Cosmetics}, Organizations {Government, Non-government}, Academic and Research Institutes, Contract Research Organizations (CRO)), Research Report, Regional Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
https://www.graphicalresearch.com/industry-insights/1851/north-america-animal-model-market
Based on application, the market is bifurcated as research and development, production and quality control, academics, preclinical applications and others. Preclinical applications segment is anticipated to expand at a CAGR of 9.2% from 2021 to 2027. The high growth of the segment is owing to numerous advantages offered by use of animal models in preclinical studies. Animal models assist the development of medical product and address several regulatory issues, further providing valuable data during the nonclinical phase. Data related to safety as well as efficacy from preclinical studies using animal models is integral in proceeding further with costly human trial phases. Genetically engineered animal models assist the preclinical researchers to address several concerns raised by the introduction of a new chemical reagent into the drug market. For instance, rasH2 model is widely used in preclinical carcinogenicity testing. Moreover, preclinical translational research of in vivo human immune system has witnessed progress in the recent years due to usage of humanized mouse models.
Based on use, the market is segmented as human and veterinary. Veterinary segment is anticipated to expand at 8.1% CAGR from 2021 to 2027. Increasing incidences of animal disorders is leading to the growing interest in research to develop veterinary vaccines and drugs. Growing trend of pet humanization and need for companionship is leading pet owners to adopt effective therapeutics that is augmenting the research and development of novel veterinary therapeutics. Moreover, veterinary contract research organizations engaged in providing animal models for veterinary drug discovery with related services has the potential to expand animal model market in North America.
Based on end-use, the market is segmented as companies, organizations, academic and research institutes and contract research organizations (CROs). Academics and research institutes segment held considerable market share in 2020 and was valued at more than USD 202 million. The considerable market share is owing to the growing demand of animal models in academics and research institutions. Academic and research institutions use animal models in order to study physiology, morphology and increase human knowledge. These institutions also use animal models to study drug toxicity. They also offer specialized resources that potentially aid academic entrepreneurs in meeting preclinical study requirements.
Canada animal model market is anticipated to expand at 11.9% CAGR and foresee a similar growth trend in the coming years. The higher market growth in the country is owing to the presence of well-established market players. The high prevalence of infectious diseases in Canada is leading scientists in the country to focus on research and development of effective therapeutics. Improving healthcare infrastructure, increasing healthcare expenditure and growing awareness pertaining to genome editing technologies are some other factors contributing to the growing demand for animal models in the country.
North American animal model market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2016 to 2027, for the following segments:
North America Market, By Animal Type
- Mice
- Rats
- Fish
- Birds
- Cattles
- Pigs
- Amphibians
- Guinea Pigs
- Dogs
- Cats
- Rabbits
- Monkeys
- Sheep
- Hamsters
- Others
North America Market, By Technology
- CRISPR
- Microinjection
- Embryonic Stem Cell Injection
- Nuclear Transfer
- Others
North America Market, By Application
- Research & Development
- Infectious Disease
- Immunological Diseases
- Cancer
- Cardiovascular Diseases
- Diabetes
- Genetic Diseases
- Neurological Diseases
- Obesity
- NAFLD/NASH
- Renal disease
- Diabetic eye disease
- Fibrosis
- Microbiome
- Others
- Production and Quality Control
- Academics
- Preclinical Applications
- Infectious Disease
- Immunological Diseases
- Cancer
- Cardiovascular Diseases
- Diabetes
- Genetic Diseases
- Neurological Diseases
- Obesity
- NAFLD/NASH
- Renal disease
- Diabetic eye disease
- Fibrosis
- Microbiome
- Others
- Others
North America Market, By Use
- Human
- Veterinary
North America Market, By End-use
- Companies
- Pharmaceutical
- Biotechnology
- Cosmetics
- Others
- Organizations
- Government
- Non-government
- Academic and Research Institutes
- Contract Research Organizations (CRO)
The above information has been provided for the following countries:
- North America
- U.S.
- Canada